Chemed Corporation $CHE Stock Position Reduced by Curated Wealth Partners LLC

Curated Wealth Partners LLC cut its holdings in shares of Chemed Corporation (NYSE:CHE) by 99.0% during the third quarter, according to its most recent filing with the Securities & Exchange Commission. The firm owned 933 shares of the company’s stock after selling 94,067 shares during the period. Curated Wealth Partners LLC’s holdings in Chemed were worth $471,000 as of its most recent SEC filing.

Other institutional investors and hedge funds also recently bought and sold shares of the company. BlackRock Inc. purchased a new position in shares of Chemed during the 2nd quarter worth approximately $691,290,000. First Trust Advisors LP increased its holdings in Chemed by 24.7% in the first quarter. First Trust Advisors LP now owns 236,392 shares of the company’s stock valued at $89,295,000 after buying an additional 46,791 shares in the last quarter. Copeland Capital Management LLC raised its position in Chemed by 7.6% during the first quarter. Copeland Capital Management LLC now owns 147,957 shares of the company’s stock worth $55,889,000 after acquiring an additional 10,406 shares during the last quarter. Allspring Global Investments Holdings LLC raised its holdings in Chemed by 7.9% in the 1st quarter. Allspring Global Investments Holdings LLC now owns 107,215 shares of the company’s stock valued at $40,481,000 after acquiring an additional 7,807 shares during the last quarter. Finally, Bank of America Corp DE acquired a new stake in shares of Chemed in the second quarter worth approximately $48,255,000. 95.85% of the stock is currently owned by institutional investors and hedge funds.

Insider Buying and Selling

In other Chemed news, EVP Spencer Lee sold 1,000 shares of the stock in a transaction dated Friday, August 21st. The stock was sold at an average price of $541.04, for a total transaction of $541,040.00. Following the completion of the transaction, the executive vice president owned 13,912 shares in the company, valued at approximately $7,526,948.48. This represents a 6.71% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Also, CEO Kevin McNamara sold 2,000 shares of the business’s stock in a transaction on Monday, August 3rd. The stock was sold at an average price of $539.51, for a total transaction of $1,079,020.00. Following the completion of the sale, the chief executive officer directly owned 70,418 shares in the company, valued at approximately $37,991,215.18. This represents a 2.76% decrease in their position. The disclosure for this sale is available in the SEC filing. In the last ninety days, insiders sold 9,190 shares of company stock valued at $4,833,160. Company insiders own 3.33% of the company’s stock.

Wall Street Analyst Weigh In

A number of analysts have recently issued reports on the stock. Bank of America reiterated a “neutral” rating on shares of Chemed in a research note on Wednesday, July 29th. Oppenheimer raised their price objective on shares of Chemed from $500.00 to $590.00 and gave the company an “outperform” rating in a research note on Friday, July 31st. Weiss Ratings raised shares of Chemed from a “hold (c)” rating to a “hold (c+)” rating in a research note on Thursday, October 8th. UBS Group assumed coverage on shares of Chemed in a research note on Friday, September 25th. They issued a “buy” rating and a $650.00 price target on the stock. Finally, Wall Street Zen raised shares of Chemed from a “buy” rating to a “strong-buy” rating in a report on Saturday, October 10th. Two analysts have rated the stock with a Buy rating and five have given a Hold rating to the company’s stock. According to MarketBeat.com, Chemed currently has a consensus rating of “Hold” and an average target price of $554.60.

Chemed Trading Down 0.6%

Shares of CHE opened at $512.20 on Friday. The company has a debt-to-equity ratio of 0.17, a quick ratio of 0.89 and a current ratio of 0.91. The stock has a fifty day moving average price of $517.57 and a two-hundred day moving average price of $471.11. Chemed Corporation has a 52-week low of $365.20 and a 52-week high of $557.00. The company has a market cap of $6.69 billion, a price-to-earnings ratio of 25.73, a PEG ratio of 2.07 and a beta of 0.51.

Chemed (NYSE:CHE) last issued its quarterly earnings results on Tuesday, July 28th. The company reported $6.06 earnings per share (EPS) for the quarter, beating the consensus estimate of $5.60 by $0.46. The business had revenue of $673.25 million for the quarter, compared to analyst estimates of $665.04 million. Chemed had a return on equity of 31.77% and a net margin of 10.60%. The firm’s revenue for the quarter was up 8.8% compared to the same quarter last year. During the same quarter in the prior year, the firm posted $4.27 earnings per share. Chemed has set its FY 2026 guidance at 25.000-25.750 EPS. Analysts predict that Chemed Corporation will post 23.55 EPS for the current fiscal year.

Chemed Increases Dividend

The firm also recently declared a quarterly dividend, which was paid on Thursday, September 3rd. Shareholders of record on Monday, August 17th were issued a $0.70 dividend. This represents a $2.80 annualized dividend and a dividend yield of 0.5%. This is an increase from Chemed’s previous quarterly dividend of $0.60. The ex-dividend date was Monday, August 17th. Chemed’s dividend payout ratio is currently 14.06%.

About Chemed

Chemed Corporation is a diversified services company headquartered in Cincinnati, Ohio. Its operations are organized through two principal businesses: VITAS Healthcare and Roto-Rooter.

VITAS Healthcare provides hospice and palliative care for patients with advanced illnesses. Its services include clinical care, pain and symptom management, emotional and spiritual support, and assistance for patients and their families in homes, hospice residences, hospitals, nursing facilities, and other care settings.